Bruno Sangro, MD, Ph.D. at Clinica Universidad de Navarro discusses The unmet need in HCC patients, the ADP-A2AFP complete response and its potential.
Dr. Bruno Sangro of Clinica Universidad de Navarro presented data from Cohort 3 and the expansion
phase of the ADP-A2AFP Phase 1 trial during an oral presentation at ILC. Tim Meyer of University College
London presented additional data from Cohorts 1 and 2 during a poster presentation. A video is
available on Adaptimmune"™s website (https://youtu.be/qAHamb3Yi8Y) of Elliot Norry, and Mark Dudley,
SVP of Early Stage Development, discussing these data. The oral presentation and poster presentation
are available online through the congress web site.
Topline data from ILC 1
"¢ One patient had a complete response and also demonstrated a sustained reduction in serum
AFP. This patient experienced disease progression, having developed new lesions at Week 32
"¢ Overall, nine patients have been treated as of the data cutoff, of those
− Four patients have been treated with ~5 billion or more transduced cells (three in
Cohort 3 and one in the expansion phase): 1 patient with the complete response, 1 with
stable disease (SD), and 2 had progressive disease (PD)
− Five patients were previously treated in the first two dose cohorts with doses of
100 million and 1 billion transduced cells, respectively, and all patients had best
responses of SD
"¢ ADP-A2AFP SPEAR T-cells were associated with an acceptable safety profile with no evidence of
significant T-cell related hepatotoxicity and no protocol-defined dose limiting toxicities
"¢ Evidence of dose-dependent persistence of ADP-A2AFP SPEAR T-cells post-infusion
"¢ Further translational evaluation is ongoing to understand indicators of response
1 All data summarized are for patients with HCC with a data cut-off of July 6, 2020. Data from non-HCC patients to
be presented at a future congress
Overview of Trial Design
"¢ This is a Phase 1, open-label, dose escalation clinical trial designed to evaluate the safety and
anti-tumor activity of ADP-A2AFP in patients with HCC or other AFP-expressing tumors who are
not amenable to transplant, resection, or loco-regional therapy, and who failed or were
intolerant to or refused standard-of-care treatment
"¢ Dose escalation is complete, and this trial is enrolling in the expansion phase intended to treat
up to 25 patients with doses up to 10 billion cells
About Adaptimmune
Adaptimmune is a clinical-stage biopharmaceutical company focused on the development of novel
cancer immunotherapy products for people with cancer. The Company"™s unique SPEAR® (Specific
Peptide Enhanced Affinity Receptor) T-cell platform enables the engineering of T-cells to target and
destroy cancer across multiple solid tumors.
Forward-Looking Statements
This release contains "forward-looking statements" within the meaning of the Private Securities
Litigation Reform Act of 1995 (PSLRA). These forward-looking statements involve certain risks and
uncertainties. Such risks and uncertainties could cause our actual results to differ materially from those
indicated by such forward-looking statements, and include, without limitation: the success, cost and
timing of our product development activities and clinical trials and our ability to successfully advance
our TCR therapeutic candidates through the regulatory and commercialization processes. For a further
description of the risks and uncertainties that could cause our actual results to differ materially from
those expressed in these forward-looking statements, as well as risks relating to our business in general,
we refer you to our Quarterly Report on Form 10-Q filed with the SEC on August 6, 2020, and our other
SEC filings. The forward-looking statements contained in this press release speak only as of the date the
statements were made and we do not undertake any obligation to update such forward-looking
statements to reflect subsequent events or circumstances.